{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T21:05:14Z","timestamp":1785186314420,"version":"3.55.0"},"reference-count":159,"publisher":"Bentham Science Publishers Ltd.","issue":"12","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDM"],"published-print":{"date-parts":[[2020,12,30]]},"abstract":"<jats:sec><jats:title>:<\/jats:title><jats:p>The clinical application of herbal medicines is increasing, but there is still a lack of comprehensive safety data and in-depth research into mechanisms of action. The composition of herbal medicines is complex, with each herb containing a variety of chemical components. Each of these components may affect the activity of metabolizing enzymes, which may lead to herb-drug interactions. It has been reported that the combined use of herbs and drugs can produce some unexpected interactions. Therefore, this study reviews the progress of research on safety issues caused by the effects of herbs on metabolizing enzymes with reference to six categories of drugs, including antithrombotic drugs, non-steroidal anti-inflammatory drugs, anti-diabetic drugs, statins lipid-lowering drugs, immunosuppressants, and antineoplastic drugs. Understanding the effects of herbs on the activity of metabolizing enzymes could help avoid the toxicity and adverse drug reactions resulting from the co-administration of herbs and drugs, and help doctors to reduce the risk of prescription incompatibility.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1389200221999200819144204","type":"journal-article","created":{"date-parts":[[2020,8,26]],"date-time":"2020-08-26T20:31:44Z","timestamp":1598473904000},"page":"913-927","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Research Progress of Herbal Medicines on Drug Metabolizing Enzymes: Consideration Based on Toxicology"],"prefix":"10.2174","volume":"21","author":[{"given":"Shuting","family":"Wang","sequence":"first","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanfang","family":"Li","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Yang","sequence":"additional","affiliation":[{"name":"Institute for Control of Chinese Traditional Medicine and Ethnic Medicine, National Institutes for Food and Drug Control, Beijing 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zengyan","family":"Yang","sequence":"additional","affiliation":[{"name":"Guangxi International Zhuang Medicine Hospital, Nanning, 530001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiping","family":"Yang","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Jin","sequence":"additional","affiliation":[{"name":"New Drug Safety Evaluation Center, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100050, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"4836","DOI":"10.2174\/092986711797535317","volume":"18","author":"Chen X.W.","year":"2011","unstructured":"Chen X.W.; Serag E.S.; Sneed K.B.; Liang J.; Chew H.; Pan S.Y.; Zhou S.F.; Clinical herbal interactions with conventional drugs: from molecules to maladies. Curr Med Chem 2011,18(31),4836-4850","journal-title":"Curr Med Chem"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1007\/s12272-011-1106-z","volume":"34","author":"Choi Y.H.","year":"2011","unstructured":"Choi Y.H.; Chin Y.W.; Kim Y.G.; Herb-drug interactions: focus on metabolic enzymes and transporters. Arch Pharm Res 2011,34(11),1843-1863","journal-title":"Arch Pharm Res"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1080\/17512433.2016.1238762","volume":"9","author":"Job K.M.","year":"2016","unstructured":"Job K.M.; Kiang T.K.; Constance J.E.; Sherwin C.M.; Enioutina E.Y.; Canada and United States. Herbal medicines: challenges in the modern world. Part 4. Expert Rev Clin Pharmacol 2016,9(12),1597-1609","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=4","first-page":"578","volume":"67","author":"Brodniewicz T.","year":"2010","unstructured":"Brodniewicz T.; Grynkiewicz G.; Preclinical drug development. Acta Pol Pharm 2010,67(6),578-585","journal-title":"Acta Pol Pharm"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1038\/nm.2471","volume":"17","author":"Tu Y.","year":"2011","unstructured":"Tu Y.; The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 2011,17(10),1217-1220","journal-title":"Nat Med"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/S0167-7799(02)02080-2","volume":"20","author":"Raskin I.","year":"2002","unstructured":"Raskin I.; Ribnicky D.M.; Komarnytsky S.; Ilic N.; Poulev A.; Borisjuk N.; Brinker A.; Moreno D.A.; Ripoll C.; Yakoby N.; O\u2019Neal J.M.; Cornwell T.; Pastor I.; Fridlender B.; Plants and human health in the twenty-first century. Trends Biotechnol 2002,20(12),522-531","journal-title":"Trends Biotechnol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1080\/17512433.2016.1195263","volume":"9","author":"Teng L.","year":"2016","unstructured":"Teng L.; Zu Q.; Li G.; Yu T.; Job K.M.; Yang X.; Di L.; Sherwin C.M.; Enioutina E.Y.; Herbal medicines: challenges in the modern world. Part 3. China and Japan. Expert Rev Clin Pharmacol 2016,9(9),1225-1233","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1080\/17512433.2016.1189326","volume":"9","author":"Sammons H.M.","year":"2016","unstructured":"Sammons H.M.; Gubarev M.I.; Krepkova L.V.; Bortnikova V.V.; Corrick F.; Job K.M.; Sherwin C.M.; Enioutina E.Y.; European Union and Russia. Herbal medicines: challenges in the modern world. Part 2. Expert Rev Clin Pharmacol 2016,9(8),1117-1127","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1080\/17512433.2017.1371591","volume":"10","author":"Enioutina E.Y.","year":"2017","unstructured":"Enioutina E.Y.; Salis E.R.; Job K.M.; Gubarev M.I.; Krepkova L.V.; Sherwin C.M.; Herbal Medicines: challenges in the modern world. Part 5. Status and current directions of complementary and alternative herbal medicine worldwide. Expert Rev Clin Pharmacol 2017,10(3),327-338","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1001\/jamainternmed.2013.2299","volume":"173","author":"Bailey R.L.","year":"2013","unstructured":"Bailey R.L.; Gahche J.J.; Miller P.E.; Thomas P.R.; Dwyer J.T.; Why US adults use dietary supplements. JAMA Intern Med 2013,173(5),355-361","journal-title":"JAMA Intern Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.drudis.2016.05.015","volume":"21","author":"Sun W.","year":"2016","unstructured":"Sun W.; Sanderson P.E.; Zheng W.; Drug combination therapy increases successful drug repositioning. Drug Discov Today 2016,21(7),1189-1195","journal-title":"Drug Discov Today"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1111\/jcmm.12930","volume":"20","author":"He B.","year":"2016","unstructured":"He B.; Lu C.; Zheng G.; He X.; Wang M.; Chen G.; Zhang G.; Lu A.; Combination therapeutics in complex diseases. J Cell Mol Med 2016,20(12),2231-2240","journal-title":"J Cell Mol Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nm.4382","volume":"23","author":"Firestone A.J.","year":"2017","unstructured":"Firestone A.J.; Settleman J.; A three-drug combination to treat BRAF-mutant cancers. Nat Med 2017,23(8),913-914","journal-title":"Nat Med"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/aps.2015.120","volume":"37","author":"Jiang Y.M.","year":"2016","unstructured":"Jiang Y.M.; Wang Y.; Tan H.S.; Yu T.; Fan X.M.; Chen P.; Zeng H.; Huang M.; Bi H.C.; Schisandrol B protects against acetaminophen-induced acute hepatotoxicity in mice via activation of the NRF2\/ARE signaling pathway. Acta Pharmacol Sin 2016,37(3),382-389","journal-title":"Acta Pharmacol Sin"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.biopha.2018.02.032","volume":"101","author":"Shengule S.","year":"2018","unstructured":"Shengule S.; Kumbhare K.; Patil D.; Mishra S.; Apte K.; Patwardhan B.; Herb-drug interaction of Nisha Amalaki and Curcuminoids with metformin in normal and diabetic condition: a disease system approach. Biomed Pharmacother 2018,101,591-598","journal-title":"Biomed Pharmacother"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.fct.2016.07.001","volume":"107","author":"Brown A. C.","year":"2017","unstructured":"Brown A. C.; Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 2 of 5 series Food Chem Toxicol 2017,107(Pt A),472-501","journal-title":"Part 2 of 5 series Food Chem Toxicol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jand.2016.06.300","volume":"116","author":"Brown A.","year":"2016","unstructured":"Brown A.; Kidney toxicity related to herbs and dietary supplements: online table of kidney toxicity cases. J Acad Nutr Diet 2016,116(9),502-519","journal-title":"J Acad Nutr Diet"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1007\/s11606-008-0632-y","volume":"23","author":"Bent S.","year":"2008","unstructured":"Bent S.; Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 2008,23(6),854-859","journal-title":"J Gen Intern Med"},{"key":"ref=19","first-page":"101","volume":"96","author":"Asher G.N.","year":"2017","unstructured":"Asher G.N.; Corbett A.H.; Hawke R.L.; Common herbal dietary supplement-drug interactions. Am Fam Physician 2017,96(2),101-107","journal-title":"Am Fam Physician"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/j.bcp.2007.01.009","volume":"73","author":"K\u00f6hle C.","year":"2007","unstructured":"K\u00f6hle C.; Bock K.W.; Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 2007,73(12),1853-1862","journal-title":"Biochem Pharmacol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/bs.irn.2017.02.010","volume":"135","author":"Singh A.","year":"2017","unstructured":"Singh A.; Zhao K.; Herb-drug interactions of commonly used Chinese medicinal herbs. Int Rev Neurobiol 2017,135,197-232","journal-title":"Int Rev Neurobiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.tibtech.2011.06.012","volume":"30","author":"Urlacher V.B.","year":"2012","unstructured":"Urlacher V.B.; Girhard M.; Cytochrome P450 monooxygenases: an update on perspectives for synthetic application. Trends Biotechnol 2012,30(1),26-36","journal-title":"Trends Biotechnol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/nrd1851","volume":"4","author":"Wienkers L.C.","year":"2005","unstructured":"Wienkers L.C.; Heath T.G.; Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005,4(10),825-833","journal-title":"Nat Rev Drug Discov"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1126\/science.286.5439.487","volume":"286","author":"Evans W.E.","year":"1999","unstructured":"Evans W.E.; Relling M.V.; Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999,286(5439),487-491","journal-title":"Science"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.biocel.2013.02.019","volume":"45","author":"Rowland A.","year":"2013","unstructured":"Rowland A.; Miners J.O.; Mackenzie P.I.; The UDP-glucuronosyltransferases: their role in drug metabolism and detoxification. Int J Biochem Cell Biol 2013,45(6),1121-1132","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.3109\/10409239509083491","volume":"30","author":"Hayes J.D.","year":"1995","unstructured":"Hayes J.D.; Pulford D.J.; The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995,30(6),445-600","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1021\/tx700079z","volume":"21","author":"Guengerich F.P.","year":"2008","unstructured":"Guengerich F.P.; Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008,21(1),70-83","journal-title":"Chem Res Toxicol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1081\/DMR-120001387","volume":"34","author":"Hollenberg P.F.","year":"2002","unstructured":"Hollenberg P.F.; Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab Rev 2002,34(1-2),17-35","journal-title":"Drug Metab Rev"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/S0009-9236(97)90190-9","volume":"61","author":"Rau S.E.","year":"1997","unstructured":"Rau S.E.; Bend J.R.; Arnold M.O.; Tran L.T.; Spence J.D.; Bailey D.G.; Grapefruit juice-terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther 1997,61(4),401-409","journal-title":"Clin Pharmacol Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1124\/dmd.117.078964","volume":"46","author":"Solanki M.","year":"2018","unstructured":"Solanki M.; Pointon A.; Jones B.; Herbert K.; Cytochrome P450 2J2: potential role in drug metabolism and cardiotoxicity. Drug Metab Dispos 2018,46(8),1053-1065","journal-title":"Drug Metab Dispos"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"5813","DOI":"10.1038\/s41598-017-05825-9","volume":"7","author":"Dong H.","year":"2017","unstructured":"Dong H.; Ma J.; Li T.; Xiao Y.; Zheng N.; Liu J.; Gao Y.; Shao J.; Jia L.; Global deregulation of ginseng products may be a safety hazard to warfarin takers: solid evidence of ginseng-warfarin interaction. Sci Rep 2017,7(1),5813","journal-title":"Sci Rep"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/sj.tpj.6500417","volume":"7","author":"Wadelius M.","year":"2007","unstructured":"Wadelius M.; Pirmohamed M.; Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 2007,7(2),99-111","journal-title":"Pharmacogenomics J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1080\/10590500701569414","volume":"25","author":"Chan P.C.","year":"2007","unstructured":"Chan P.C.; Xia Q.; Fu P.P.; Ginkgo biloba leave extract: biological, medicinal, and toxicological effects. J. Environ. Sci. Health. C Environ Carcinog Ecotoxicol Rev 2007,25(3),211-244","journal-title":"C Environ Carcinog Ecotoxicol Rev"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/01.mjt.0000143695.68285.31","volume":"13","author":"Mohutsky M.A.","year":"2006","unstructured":"Mohutsky M.A.; Anderson G.D.; Miller J.W.; Elmer G.W.; Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther 2006,13(1),24-31","journal-title":"Am J Ther"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1212\/WNL.50.6.1933","volume":"50","author":"Matthews M.K.","year":"1998","unstructured":"Matthews M.K.; Jr Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998,50(6),1933-1934","journal-title":"Neurology"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/978-3-642-29423-5_6","author":"Patrono C.","year":"2012","unstructured":"Patrono C.; Rocca B.; Aspirin and Other COX-1 inhibitors. Handb Exp Pharmacol 2012(210),137-164","journal-title":"Handb Exp Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"804","DOI":"10.7326\/M15-2113","volume":"164","author":"Guirguis-Blake J.M.","year":"2016","unstructured":"Guirguis-Blake J.M.; Evans C.V.; Senger C.A.; O\u2019Connor E.A.; Whitlock E.P.; Aspirin for the primary prevention of cardiovascular events: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2016,164(12),804-813","journal-title":"Ann Intern Med"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1517\/14740338.1.3.245","volume":"1","author":"Lanas A.","year":"2002","unstructured":"Lanas A.; Ferr\u00e1ndez A.; Treatment and prevention of aspirin-induced gastroduodenal ulcers and gastrointestinal bleeding. Expert Opin Drug Saf 2002,1(3),245-252","journal-title":"Expert Opin Drug Saf"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1002\/ptr.5848","volume":"31","author":"Song H.","year":"2017","unstructured":"Song H.; Wang P.; Liu J.; Wang C.; Panax notoginseng preparations for unstable Angina Pectoris: a systematic review and meta-analysis. Phytother Res 2017,31(8),1162-1172","journal-title":"Phytother Res"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"3144","DOI":"10.3390\/ijms19103144","volume":"19","author":"Sun Z.","year":"2018","unstructured":"Sun Z.; Wu Y.; Liu S.; Hu S.; Zhao B.; Li P.; Du S.; Effects of Panax notoginseng saponins on esterases responsible for aspirin hydrolysis in vitro. Int J Mol Sci 2018,19(10),3144","journal-title":"Int J Mol Sci"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jchromb.2016.12.007","volume":"1040","author":"Tian Z.","year":"2017","unstructured":"Tian Z.; Pang H.; Du S.; Lu Y.; Zhang L.; Wu H.; Guo S.; Wang M.; Zhang Q.; Effect of Panax notoginseng saponins on the pharmacokinetics of aspirin in rats. J Chromatogr B Analyt Technol Biomed Life Sci 2017,1040,136-143","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/j.jep.2012.07.029","volume":"143","author":"Zhou L.","year":"2012","unstructured":"Zhou L.; Wang S.; Zhang Z.; Lau B.S.; Fung K.P.; Leung P.C.; Zuo Z.; Pharmacokinetic and pharmacodynamic interaction of Danshen-Gegen extract with warfarin and aspirin. J Ethnopharmacol 2012,143(2),648-655","journal-title":"J Ethnopharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1124\/dmd.105.005652","volume":"34","author":"Kuehl G.E.","year":"2006","unstructured":"Kuehl G.E.; Bigler J.; Potter J.D.; Lampe J.W.; Glucuronidation of the aspirin metabolite salicylic acid by expressed UDP-glucuronosyltransferases and human liver microsomes. Drug Metab Dispos 2006,34(2),199-202","journal-title":"Drug Metab Dispos"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.3109\/13880209.2015.1045621","volume":"55","author":"Zhang X.X.","year":"2017","unstructured":"Zhang X.X.; Cao Y.F.; Wang L.X.; Yuan X.L.; Fang Z.Z.; Inhibitory effects of tanshinones towards the catalytic activity of UDP-glucuronosyltransferases (UGTs). Pharm Biol 2017,55(1),1703-1709","journal-title":"Pharm Biol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1124\/dmd.30.4.378","volume":"30","author":"Chang T.K.H.","year":"2002","unstructured":"Chang T.K.H.; Chen J.; Benetton S.A.; In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 2002,30(4),378-384","journal-title":"Drug Metab Dispos"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1124\/dmd.119.087965","volume":"47","author":"Lee H.","year":"2019","unstructured":"Lee H.; Heo J.K.; Lee G.H.; Park S.Y.; Jang S.N.; Kim H.J.; Kwon M.J.; Song I.S.; Liu K.H.; Ginsenoside rc is a new selective UGT1A9 inhibitor in human liver microsomes and recombinant human UGT isoforms. Drug Metab Dispos 2019,47(12),1372-1379","journal-title":"Drug Metab Dispos"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/j.jep.2012.11.030","volume":"145","author":"Gao J.","year":"2013","unstructured":"Gao J.; Shi Z.; Zhu S.; Li G.Q.; Yan R.; Yao M.; Influences of processed rhubarbs on the activities of four CYP isozymes and the metabolism of saxagliptin in rats based on probe cocktail and pharmacokinetics approaches. J Ethnopharmacol 2013,145(2),566-572","journal-title":"J Ethnopharmacol"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jep.2013.01.028","volume":"146","author":"Su T.","year":"2013","unstructured":"Su T.; Mao C.; Yin F.; Yu Z.; Lin Y.; Song Y.; Lu T.; Effects of unprocessed versus vinegar-processed Schisandra chinensis on the activity and mRNA expression of CYP1A2, CYP2E1 and CYP3A4 enzymes in rats. J Ethnopharmacol 2013,146(3),734-743","journal-title":"J Ethnopharmacol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jep.2013.11.016","volume":"151","author":"Huang Y.","year":"2014","unstructured":"Huang Y.; Zheng S.L.; Zhu H.Y.; Xu Z.S.; Xu R.A.; Effects of aescin on cytochrome P450 enzymes in rats. J Ethnopharmacol 2014,151(1),583-590","journal-title":"J Ethnopharmacol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/j.jfda.2017.11.005","volume":"26","author":"Yu C.P.","year":"2018","unstructured":"Yu C.P.; Huang C.Y.; Lin S.P.; Hou Y.C.; Activation of P-glycoprotein and CYP 3A by Coptidis rhizoma in vivo: using cyclosporine as a probe substrate in rats. Yao Wu Shi Pin Fen Xi 2018,26(2S),S125-S132","journal-title":"Yao Wu Shi Pin Fen Xi"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lfs.2017.09.011","volume":"189","author":"Jiang B.","year":"2017","unstructured":"Jiang B.; Meng L.; Zhang F.; Jin X.; Zhang G.; Enzyme-inducing effects of berberine on cytochrome P450 1A2 in vitro and in vivo. Life Sci 2017,189,1-7","journal-title":"Life Sci"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/toxsci\/66.1.27","volume":"66","author":"Bray B.J.","year":"2002","unstructured":"Bray B.J.; Perry N.B.; Menkes D.B.; Rosengren R.J.St.; John\u2019s wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002,66(1),27-33","journal-title":"Toxicol Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1186\/s12906-018-2402-7","volume":"18","author":"Feng D.","year":"2018","unstructured":"Feng D.; Tang T.; Fan R.; Luo J.; Cui H.; Wang Y.; Gan P.; Gancao (Glycyrrhizae Radix) provides the main contribution to Shaoyao-Gancao decoction on enhancements of CYP3A4 and MDR1 expression via pregnane X receptor pathway in vitro. BMC Complement Altern Med 2018,18(1),345","journal-title":"BMC Complement Altern Med"},{"key":"ref=54","first-page":"1033","volume":"24","author":"Yang X-F.","year":"2003","unstructured":"Yang X-F.; Wang N-P.; Lu W-H.; Zeng F-D.; Effects of Ginkgo biloba extract and tanshinone on cytochrome P-450 isozymes and glutathione transferase in rats. Acta Pharmacol Sin 2003,24(10),1033-1038","journal-title":"Acta Pharmacol Sin"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1124\/dmd.109.028118","volume":"37","author":"Lau A.J.","year":"2009","unstructured":"Lau A.J.; Chang T.K.; Inhibition of human CYP2B6-catalyzed bupropion hydroxylation by Ginkgo biloba extract: effect of terpene trilactones and flavonols. Drug Metab Dispos 2009,37(9),1931-1937","journal-title":"Drug Metab Dispos"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"16511","DOI":"10.1038\/s41598-017-16688-5","volume":"7","author":"Xu S.","year":"2017","unstructured":"Xu S.; Liu J.; Shi J.; Wang Z.; Ji L.; 2,3,4\u2032,5-tetrahydroxystilbene-2-O-\u03b2-D-glucoside exacerbates acetaminophen-induced hepatotoxicity by inducing hepatic expression of CYP2E1, CYP3A4 and CYP1A2. Sci Rep 2017,7(1),16511","journal-title":"Sci Rep"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/bdd.1918","volume":"36","author":"Chen X.","year":"2015","unstructured":"Chen X.; Jin J.; Chen Y.; Peng L.; Zhong G.; Li J.; Bi H.; Cai Y.; Huang M.; Effect of scutellarin on the metabolism and pharmacokinetics of clopidogrel in rats. Biopharm Drug Dispos 2015,36(1),64-68","journal-title":"Biopharm Drug Dispos"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/5651989","volume":"2018","author":"Ma S.","year":"2018","unstructured":"Ma S.; Dai G.; Bi X.; Gong M.; Miao C.; Chen H.; Gao L.; Zhao W.; Liu T.; Zhang N.; The herb-drug interaction of Clopidogrel and Xuesaitong dispersible tablet by modulation of the pharmacodynamics and liver carboxylesterase 1A metabolism. Evid Based Complement Alternat Med 2018,2018(3),1-8","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=59","doi-asserted-by":"crossref","first-page":"e8651","DOI":"10.1002\/rcm.8651","volume":"34","author":"Singh A.","year":"2019","unstructured":"Singh A.; Zhao K.; Bell C.; Shah A.J.; Effect of berberine on in vitro metabolism of sulfonylureas: a herb-drug interactions study. Rapid Commun Mass Spectrom 2019,34(Sup 4),e8651","journal-title":"Rapid Commun Mass Spectrom"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1038\/sj.bjp.0707685","volume":"153","author":"Xu H.","year":"2008","unstructured":"Xu H.; Williams K.M.; Liauw W.S.; Murray M.; Day R.O.; McLachlan A.J.; Effects of St John\u2019s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide. Br J Pharmacol 2008,153(7),1579-1586","journal-title":"Br J Pharmacol"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jpba.2018.01.010","volume":"151","author":"Sahu R.","year":"2018","unstructured":"Sahu R.; Ahmed T.; Sangana R.; Punde R.; Subudhi B.B.; Effect of Tinospora cordifolia aqua-alcoholic extract on pharmacokinetic of Glibenclamide in rat: an herb-drug interaction study. J Pharm Biomed Anal 2018,151,310-316","journal-title":"J Pharm Biomed Anal"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.3389\/fphar.2019.01243","volume":"10","author":"Patel O.","year":"2019","unstructured":"Patel O.; Muller C.J.F.; Joubert E.; Rosenkranz B.; Taylor M.J.C.; Louw J.; Awortwe C.; Pharmacokinetic interaction of green rooibos extract with atorvastatin and metformin in rats. Front Pharmacol 2019,10,1243","journal-title":"Front Pharmacol"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"4967","DOI":"10.1021\/acs.jafc.9b00846","volume":"67","author":"Fantoukh O.I.","year":"2019","unstructured":"Fantoukh O.I.; Dale O.R.; Parveen A.; Hawwal M.F.; Ali Z.; Manda V.K.; Khan S.I.; Chittiboyina A.G.; Viljoen A.; Khan I.A.; Safety assessment of phytochemicals derived from the globalized South African rooibos tea (Aspalathus linearis) through interaction with CYP, PXR, and P-gp. J Agric Food Chem 2019,67(17),4967-4975","journal-title":"J Agric Food Chem"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1007\/s00228-007-0345-x","volume":"63","author":"Andr\u00e9n L.","year":"2007","unstructured":"Andr\u00e9n L.; Andreasson A.; Eggertsen R.; Interaction between a commercially available St. John\u2019s wort product (Movina) and atorvastatin in patients with hypercholesterolemia. Eur J Clin Pharmacol 2007,63(10),913-916","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1080\/13880209.2019.1622569","volume":"57","author":"Ren Y.","year":"2019","unstructured":"Ren Y.; Li H.; Liu X.; Effects of Ginkgo leaf tablets on the pharmacokinetics of atovastatin in rats. Pharm Biol 2019,57(1),403-406","journal-title":"Pharm Biol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S0168-8278(00)80321-9","volume":"33","author":"Karliova M.","year":"2000","unstructured":"Karliova M.; Treichel U.; Malag\u00f2 M.; Frilling A.; Gerken G.; Broelsch C.E.; Interaction of Hypericum perforatum (St. John\u2019s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000,33(5),853-855","journal-title":"J Hepatol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1016\/S0140-6736(99)05467-7","volume":"355","author":"Ruschitzka F.","year":"2000","unstructured":"Ruschitzka F.; Meier P.J.; Turina M.; L\u00fcscher T.F.; Noll G.; Acute heart transplant rejection due to Saint John\u2019s wort. Lancet 2000,355(9203),548-549","journal-title":"Lancet"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1053\/ajkd.2001.28617","volume":"38","author":"Moschella C.","year":"2001","unstructured":"Moschella C.; Jaber B.L.; Interaction between cyclosporine and Hypericum perforatum (St. John\u2019s wort) after organ transplantation. Am J Kidney Dis 2001,38(5),1105-1107","journal-title":"Am J Kidney Dis"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1016\/j.foodchem.2012.07.061","volume":"135","author":"Hou Y.C.","year":"2012","unstructured":"Hou Y.C.; Lin S.P.; Chao P.D.; Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A. Food Chem 2012,135(4),2307-2312","journal-title":"Food Chem"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1089\/jmf.2011.1596","volume":"14","author":"Lin S.P.","year":"2011","unstructured":"Lin S.P.; Chao P.D.; Tsai S.Y.; Wang M.J.; Hou Y.C.; Citrus grandis peel increases the bioavailability of cyclosporine and tacrolimus, two important immunosuppressants, in rats. J Med Food 2011,14(11),1463-1468","journal-title":"J Med Food"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"242","DOI":"10.2133\/dmpk.DMPK-11-RG-105","volume":"27","author":"Egashira K.","year":"2012","unstructured":"Egashira K.; Sasaki H.; Higuchi S.; Ieiri I.; Food-drug interaction of tacrolimus with pomelo, ginger, and turmeric juice in rats. Drug Metab Pharmacokinet 2012,27(2),242-247","journal-title":"Drug Metab Pharmacokinet"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1111\/jcpt.13002","volume":"44","author":"Zhai X.","year":"2019","unstructured":"Zhai X.; Chen C.; Xu X.; Ma L.; Zhou S.; Wang Z.; Ma L.; Zhao X.; Zhou Y.; Cui Y.; Marked change in blood tacrolimus concentration levels due to grapefruit in a renal transplant patient. J Clin Pharm Ther 2019,44(5),819-822","journal-title":"J Clin Pharm Ther"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.transproceed.2016.11.029","volume":"49","author":"Nayeri A.","year":"2017","unstructured":"Nayeri A.; Wu S.; Adams E.; Tanner C.; Meshman J.; Saini I.; Reid W.; Acute calcineurin inhibitor nephrotoxicity secondary to turmeric intake: a case report. Transplant Proc 2017,49(1),198-200","journal-title":"Transplant Proc"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1007\/s11095-005-4585-0","volume":"22","author":"Hu Z.","year":"2005","unstructured":"Hu Z.; Yang X.; Ho P.C.; Chan E.; Chan S.Y.; Xu C.; Li X.; Zhu Y.Z.; Duan W.; Chen X.; Huang M.; Yang H.; Zhou S.St.; John\u2019s Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharm Res 2005,22(6),902-914","journal-title":"Pharm Res"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1093\/jnci\/94.16.1247","volume":"94","author":"Mathijssen R.H.J.","year":"2002","unstructured":"Mathijssen R.H.J.; Verweij J.; de Bruijn P.; Loos W.J.; Sparreboom A.; Effects of St. John\u2019s wort on irinotecan metabolism. J Natl Cancer Inst 2002,94(16),1247-1249","journal-title":"J Natl Cancer Inst"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.steroids.2013.11.015","volume":"80","author":"Man S.","year":"2014","unstructured":"Man S.; Li Y.; Fan W.; Gao W.; Liu Z.; Zhang Y.; Liu C.; Combination therapy of cyclophosphamide and Rhizoma Paridis Saponins on anti-hepatocarcinoma mice and effects on cytochrome p450 enzyme expression. Steroids 2014,80,1-6","journal-title":"Steroids"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40262-014-0230-6","volume":"54","author":"Jiang X.L.","year":"2015","unstructured":"Jiang X.L.; Samant S.; Lesko L.J.; Schmidt S.; Clinical pharmacokinetics and pharmacodynamics of clopidogrel. Clin Pharmacokinet 2015,54(2),147-166","journal-title":"Clin Pharmacokinet"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1007\/s11239-019-01945-3","volume":"48","author":"Hu Y.","year":"2019","unstructured":"Hu Y.; Wang J.; Interactions between clopidogrel and traditional Chinese medicine. J Thromb Thrombolysis 2019,48(3),491-499","journal-title":"J Thromb Thrombolysis"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1097\/FJC.0b013e3180cbd0e7","volume":"50","author":"Lin L-L.","year":"2007","unstructured":"Lin L-L.; Liu A-J.; Liu J-G.; Yu X-H.; Qin L-P.; Su D-F.; Protective effects of scutellarin and breviscapine on brain and heart ischemia in rats. J Cardiovasc Pharmacol 2007,50(3),327-332","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.clpt.2006.07.007","volume":"80","author":"Taubert D.","year":"2006","unstructured":"Taubert D.; von Beckerath N.; Grimberg G.; Lazar A.; Jung N.; Goeser T.; Kastrati A.; Sch\u00f6mig A.; Sch\u00f6mig E.; Impact of P-glycoprotein on clopidogrel absorption. Clin Pharmacol Ther 2006,80(5),486-501","journal-title":"Clin Pharmacol Ther"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12906-015-0560-4","volume":"15","author":"Zhang X.","year":"2015","unstructured":"Zhang X.; Wu J.; Zhang B.; Xuesaitong injection as one adjuvant treatment of acute cerebral infarction: a systematic review and meta-analysis. BMC Complement Altern Med 2015,15,36","journal-title":"BMC Complement Altern Med"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1159\/000374090","volume":"33","author":"Jaeschke H.","year":"2015","unstructured":"Jaeschke H.; Acetaminophen: Dose-dependent drug hepatotoxicity and acute liver failure in patients. Dig Dis 2015,33(4),464-471","journal-title":"Dig Dis"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/toxsci\/kfi211","volume":"87","author":"Kostrubsky S.E.","year":"2005","unstructured":"Kostrubsky S.E.; Sinclair J.F.; Strom S.C.; Wood S.; Urda E.; Stolz D.B.; Wen Y.H.; Kulkarni S.; Mutlib A.; Phenobarbital and phenytoin increased acetaminophen hepatotoxicity due to inhibition of UDP-glucuronosyltransferases in cultured human hepatocytes. Toxicol Sci 2005,87(1),146-155","journal-title":"Toxicol Sci"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139299","volume":"10","author":"Kaur G.","year":"2015","unstructured":"Kaur G.; Leslie E.M.; Tillman H.; Lee W.M.; Swanlund D.P.; Karvellas C.J.; Group U.S.A.L.F.S.; US acute liver failure study group. detection of ophthalmic acid in serum from acetaminophen-induced acute liver failure patients is more frequent in non-survivors. PLoS One 2015,10(9)","journal-title":"PLoS One"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"15501","DOI":"10.1038\/srep15501","volume":"5","author":"Vliegenthart A.D.","year":"2015","unstructured":"Vliegenthart A.D.; Shaffer J.M.; Clarke J.I.; Peeters L.E.; Caporali A.; Bateman D.N.; Wood D.M.; Dargan P.I.; Craig D.G.; Moore J.K.; Thompson A.I.; Henderson N.C.; Webb D.J.; Sharkey J.; Antoine D.J.; Park B.K.; Bailey M.A.; Lader E.; Simpson K.J.; Dear J.W.; Comprehensive microRNA profiling in acetaminophen toxicity identifies novel circulating biomarkers for human liver and kidney injury. Sci Rep 2015,5,15501","journal-title":"Sci Rep"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1124\/dmd.111.039602","volume":"39","author":"Mohamed M.E.","year":"2011","unstructured":"Mohamed M.E.; Frye R.F.; Inhibitory effects of commonly used herbal extracts on UDP-glucuronosyltransferase 1A4, 1A6, and 1A9 enzyme activities. Drug Metab Dispos 2011,39(9),1522-1528","journal-title":"Drug Metab Dispos"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.jep.2014.11.009","volume":"159","author":"Lin L.","year":"2015","unstructured":"Lin L.; Ni B.; Lin H.; Zhang M.; Li X.; Yin X.; Qu C.; Ni J.; Traditional usages, botany, phytochemistry, pharmacology and toxicology of Polygonum multiflorum Thunb.: a review. J Ethnopharmacol 2015,159,158-183","journal-title":"J Ethnopharmacol"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/nrendo.2016.86","volume":"12","author":"Tahrani A.A.","year":"2016","unstructured":"Tahrani A.A.; Barnett A.H.; Bailey C.J.; Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus. Nat Rev Endocrinol 2016,12(10),566-592","journal-title":"Nat Rev Endocrinol"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S2213-8587(14)70213-X","volume":"3","author":"Simpson S.H.","year":"2015","unstructured":"Simpson S.H.; Lee J.; Choi S.; Vandermeer B.; Abdelmoneim A.S.; Featherstone T.R.; Mortality risk among sulfonylureas: a systematic review and network meta-analysis. Lancet Diabetes Endocrinol 2015,3(1),43-51","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1007\/s11892-017-0954-4","volume":"17","author":"Pop L.M.","year":"2017","unstructured":"Pop L.M.; Lingvay I.; The infamous, famous sulfonylureas and cardiovascular safety: much ado about nothing? Curr Diab Rep 2017,17(12),124","journal-title":"Curr Diab Rep"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00228-011-1078-4","volume":"67","author":"G\u00f6kalp O.","year":"2011","unstructured":"G\u00f6kalp O.; Gunes A.; Cam H.; Cure E.; Ayd\u0131n O.; Tamer M.N.; Scordo M.G.; Dahl M.L.; Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol 2011,67(12),1223-1229","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=92","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0082880","volume":"9","author":"Landman G.W.","year":"2014","unstructured":"Landman G.W.; de Bock G.H.; van Hateren K.J.; van Dijk P.R.; Groenier K.H.; Gans R.O.; Houweling S.T.; Bilo H.J.; Kleefstra N.; Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. PLoS One 2014,9(2)","journal-title":"PLoS One"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/aps.2016.125","volume":"38","author":"Zou K.","year":"2017","unstructured":"Zou K.; Li Z.; Zhang Y.; Zhang H.Y.; Li B.; Zhu W.L.; Shi J.Y.; Jia Q.; Li Y.M.; Advances in the study of berberine and its derivatives: a focus on anti-inflammatory and anti-tumor effects in the digestive system. Acta Pharmacol Sin 2017,38(2),157-167","journal-title":"Acta Pharmacol Sin"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"362","DOI":"10.3389\/fphar.2016.00362","volume":"7","author":"Tan H-L.","year":"2016","unstructured":"Tan H-L.; Chan K-G.; Pusparajah P.; Duangjai A.; Saokaew S.; Mehmood Khan T.; Lee L-H.; Goh B-H.; Rhizoma coptidis: a Potential Cardiovascular Protective Agent. Front Pharmacol 2016,7,362","journal-title":"Front Pharmacol"},{"key":"ref=95","first-page":"88","volume":"294","author":"Obach R.S.","year":"2000","unstructured":"Obach R.S.; Inhibition of human cytochrome P450 enzymes by constituents of St. John\u2019s Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000,294(1),88-95","journal-title":"J Pharmacol Exp Ther"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1124\/dmd.32.5.512","volume":"32","author":"Komoroski B.J.","year":"2004","unstructured":"Komoroski B.J.; Zhang S.; Cai H.; Hutzler J.M.; Frye R.; Tracy T.S.; Strom S.C.; Lehmann T.; Ang C.Y.W.; Cui Y.Y.; Venkataramanan R.; Induction and inhibition of cytochromes P450 by the St. John\u2019s wort constituent hyperforin in human hepatocyte cultures. Drug Metab Dispos 2004,32(5),512-518","journal-title":"Drug Metab Dispos"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1002\/bmc.2830","volume":"27","author":"Ravindran S.","year":"2013","unstructured":"Ravindran S.; Basu S.; Gorti S.K.; Surve P.; Sloka N.; Metabolic profile of glyburide in human liver microsomes using LC-DAD-Q-TRAP-MS\/MS. Biomed Chromatogr 2013,27(5),575-582","journal-title":"Biomed Chromatogr"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/pds.4014","volume":"25","author":"Abdelmoneim A.S.","year":"2016","unstructured":"Abdelmoneim A.S.; Eurich D.T.; Senthilselvan A.; Qiu W.; Simpson S.H.; Dose-response relationship between sulfonylureas and major adverse cardiovascular events in elderly patients with type 2 diabetes. Pharmacoepidemiol Drug Saf 2016,25(10),1186-1195","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1002\/bdd.706","volume":"31","author":"Zhou L.","year":"2010","unstructured":"Zhou L.; Naraharisetti S.B.; Liu L.; Wang H.; Lin Y.S.; Isoherranen N.; Unadkat J.D.; Hebert M.F.; Mao Q.; Contributions of human cytochrome P450 enzymes to glyburide metabolism. Biopharm Drug Dispos 2010,31(4),228-242","journal-title":"Biopharm Drug Dispos"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1186\/s12906-017-1953-3","volume":"17","author":"Polu P.R.","year":"2017","unstructured":"Polu P.R.; Nayanbhirama U.; Khan S.; Maheswari R.; Assessment of free radical scavenging and anti-proliferative activities of Tinospora cordifolia Miers (Willd). BMC Complement Altern Med 2017,17(1),457","journal-title":"BMC Complement Altern Med"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"93","DOI":"10.2165\/00003088-200746020-00001","volume":"46","author":"Scheen A.J.","year":"2007","unstructured":"Scheen A.J.; Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 2007,46(2),93-108","journal-title":"Clin Pharmacokinet"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejphar.2018.03.025","volume":"828","author":"Takahashi H.","year":"2018","unstructured":"Takahashi H.; Hidaka S.; Seki C.; Yokoi N.; Seino S.; Characteristics of repaglinide effects on insulin secretion. Eur J Pharmacol 2018,828,52-59","journal-title":"Eur J Pharmacol"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/obr.12753","volume":"20","author":"Jia Y.","year":"2019","unstructured":"Jia Y.; Lao Y.; Zhu H.; Li N.; Leung S.W.; Is metformin still the most efficacious first-line oral hypoglycaemic drug in treating type 2 diabetes? A network meta-analysis of randomized controlled trials. Obes Rev 2019,20(1),1-12","journal-title":"Obes Rev"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1046\/j.0306-5251.2003.01862.x","volume":"56","author":"Bidstrup T.B.","year":"2003","unstructured":"Bidstrup T.B.; Bj\u00f8rnsdottir I.; Sidelmann U.G.; Thomsen M.S.; Hansen K.T.; CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003,56(3),305-314","journal-title":"Br J Clin Pharmacol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1515\/dmpt-2015-0046","volume":"31","author":"Goud T.","year":"2016","unstructured":"Goud T.; Maddi S.; Nayakanti D.; Thatipamula R.P.; Altered pharmacokinetics and pharmacodynamics of repaglinide by ritonavir in rats with healthy, diabetic and impaired hepatic function. Drug Metab Pers Ther 2016,31(2),123-130","journal-title":"Drug Metab Pers Ther"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1007\/s40262-019-00777-x","volume":"58","author":"T\u00fcrk D.","year":"2019","unstructured":"T\u00fcrk D.; Hanke N.; Wolf S.; Frechen S.; Eissing T.; Wendl T.; Schwab M.; Lehr T.; Physiologically based pharmacokinetic models for prediction of complex CYP2C8 and OATP1B1 (SLCO1B1) drug-drug-gene interactions: a modeling network of gemfibrozil, repaglinide, pioglitazone, rifampicin, clarithromycin and itraconazole. Clin Pharmacokinet 2019,58(12),1595-1607","journal-title":"Clin Pharmacokinet"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1046\/j.1365-2125.2003.02027.x","volume":"57","author":"Niemi M.","year":"2004","unstructured":"Niemi M.; Kajosaari L.I.; Neuvonen M.; Backman J.T.; Neuvonen P.J.; The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects. Br J Clin Pharmacol 2004,57(4),441-447","journal-title":"Br J Clin Pharmacol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1592\/phco.28.5.682","volume":"28","author":"Khamaisi M.","year":"2008","unstructured":"Khamaisi M.; Leitersdorf E.; Severe hypoglycemia from clarithromycin-repaglinide drug interaction. Pharmacotherapy 2008,28(5),682-684","journal-title":"Pharmacotherapy"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1515\/dmdi-2013-0031","volume":"28","author":"Poonam T.","year":"2013","unstructured":"Poonam T.; Prakash G.P.; Kumar L.V.; Influence of Allium sativum extract on the hypoglycemic activity of glibenclamide: an approach to possible herb-drug interaction. Drug Metabol Drug Interact 2013,28(4),225-230","journal-title":"Drug Metabol Drug Interact"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1517\/17425255.2015.1056149","volume":"11","author":"Hirota T.","year":"2015","unstructured":"Hirota T.; Ieiri I.; Drug-drug interactions that interfere with statin metabolism. Expert Opin Drug Metab Toxicol 2015,11(9),1435-1447","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"5041","DOI":"10.1039\/C8FO01010B","volume":"9","author":"Smith C.","year":"2018","unstructured":"Smith C.; Swart A.; Aspalathus linearis (Rooibos)-a functional food targeting cardiovascular disease. Food Funct 2018,9(10),5041-5058","journal-title":"Food Funct"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1080\/13880209.2018.1424209","volume":"56","author":"Sun S.","year":"2018","unstructured":"Sun S.; Wang R.; Fan J.; Zhang G.; Zhang H.; Effects of Danshen tablets on pharmacokinetics of atorvastatin calcium in rats and its potential mechanism. Pharm Biol 2018,56(1),104-108","journal-title":"Pharm Biol"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2016.02.012","volume":"107","author":"Cortese F.","year":"2016","unstructured":"Cortese F.; Gesualdo M.; Cortese A.; Carbonara S.; Devito F.; Zito A.; Ricci G.; Scicchitano P.; Ciccone M.M.; Rosuvastatin: Beyond the cholesterol-lowering effect. Pharmacol Res 2016,107,1-18","journal-title":"Pharmacol Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1586\/14779072.1.4.495","volume":"1","author":"Rosenson R.S.","year":"2003","unstructured":"Rosenson R.S.; Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia. Expert Rev Cardiovasc Ther 2003,1(4),495-505","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pcad.2004.04.007","volume":"47","author":"Davidson M.H.","year":"2004","unstructured":"Davidson M.H.; Toth P.P.; Comparative effects of lipid-lowering therapies. Prog Cardiovasc Dis 2004,47(2),73-104","journal-title":"Prog Cardiovasc Dis"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/jphp.13045","volume":"71","author":"Liu R.","year":"2019","unstructured":"Liu R.; Dobson C.C.; Foster B.C.; Durst T.; Sanchez P.; Arnason J.T.; Harris C.S.; Effect of an anxiolytic botanical containing Souroubea sympetala and Platanus occidentalis on in-vitro diazepam human cytochrome P450-mediated metabolism. J Pharm Pharmacol 2019,71(3),429-437","journal-title":"J Pharm Pharmacol"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13318-011-0048-7","volume":"36","author":"Wen J.H.","year":"2011","unstructured":"Wen J.H.; Xiong Y.Q.; The effect of herbal medicine danshensu and ursolic acid on pharmacokinetics of rosuvastatin in rats. Eur J Drug Metab Pharmacokinet 2011,36(4),205-211","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"S132","DOI":"10.1002\/jcph.669","volume":"56","author":"Emami Riedmaier A.","year":"2016","unstructured":"Emami Riedmaier A.; Burt H.; Abduljalil K.; Neuhoff S.; More power to OATP1B1: An evaluation of sample size in pharmacogenetic studies using a rosuvastatin PBPK model for intestinal, hepatic, and renal transporter-mediated clearances. J Clin Pharmacol 2016,56(Suppl. 7),S132-S142","journal-title":"J Clin Pharmacol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"247","DOI":"10.2165\/00129784-200404040-00005","volume":"4","author":"Vermes A.","year":"2004","unstructured":"Vermes A.; Vermes I.; Genetic polymorphisms in cytochrome P450 enzymes: effect on efficacy and tolerability of HMG-CoA reductase inhibitors. Am J Cardiovasc Drugs 2004,4(4),247-255","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/ni.3640","volume":"18","author":"Dutta D.","year":"2017","unstructured":"Dutta D.; Barr V.A.; Akpan I.; Mittelstadt P.R.; Singha L.I.; Samelson L.E.; Ashwell J.D.; Recruitment of calcineurin to the TCR positively regulates T cell activation. Nat Immunol 2017,18(2),196-204","journal-title":"Nat Immunol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/17401","volume":"397","author":"Hojo M.","year":"1999","unstructured":"Hojo M.; Morimoto T.; Maluccio M.; Asano T.; Morimoto K.; Lagman M.; Shimbo T.; Suthanthiran M.; Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999,397(6719),530-534","journal-title":"Nature"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/B0-12-369400-0\/00283-0","author":"Dodd-Butera T.","year":"2005","unstructured":"Dodd-Butera T.; Broderick M.; Encyclopedia of Toxicology 2nd ed 2005,711-713","journal-title":"Encyclopedia of Toxicology 2nd ed"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/tpj.2010.26","volume":"11","author":"Zhu H.J.","year":"2011","unstructured":"Zhu H.J.; Yuan S.H.; Fang Y.; Sun X.Z.; Kong H.; Ge W.H.; The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis. Pharmacogenomics J 2011,11(3),237-246","journal-title":"Pharmacogenomics J"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"677","DOI":"10.3109\/00498254.2015.1117159","volume":"46","author":"Yu C.P.","year":"2016","unstructured":"Yu C.P.; Lin H.J.; Lin S.P.; Shia C.S.; Chang P.H.; Hou Y.C.; Hsieh Y.W.; Rhubarb decreased the systemic exposure of cyclosporine, a probe substrate of P-glycoprotein and CYP 3A. Xenobiotica 2016,46(8),677-682","journal-title":"Xenobiotica"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1039\/C6FO00938G","volume":"8","author":"Yang M.S.","year":"2017","unstructured":"Yang M.S.; Yu C.P.; Huang C.Y.; Chao P.L.; Lin S.P.; Hou Y.C.; Aloe activated P-glycoprotein and CYP 3A: a study on the serum kinetics of aloe and its interaction with cyclosporine in rats. Food Funct 2017,8(1),315-322","journal-title":"Food Funct"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1021\/jf104786t","volume":"59","author":"Yu C.P.","year":"2011","unstructured":"Yu C.P.; Wu P.P.; Hou Y.C.; Lin S.P.; Tsai S.Y.; Chen C.T.; Chao P.D.; Quercetin and rutin reduced the bioavailability of cyclosporine from Neoral, an immunosuppressant, through activating P-glycoprotein and CYP 3A4. J Agric Food Chem 2011,59(9),4644-4648","journal-title":"J Agric Food Chem"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1021\/jf3052384","volume":"61","author":"Hsu P.W.","year":"2013","unstructured":"Hsu P.W.; Shia C.S.; Lin S.P.; Chao P.D.; Juang S.H.; Hou Y.C.; Potential risk of mulberry-drug interaction: modulation on P-glycoprotein and cytochrome P450 3A. J Agric Food Chem 2013,61(18),4464-4469","journal-title":"J Agric Food Chem"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1080\/10408398.2015.1077195","volume":"57","author":"Kocaadam B.","year":"2017","unstructured":"Kocaadam B.; \u015eanlier N.; Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2017,57(13),2889-2895","journal-title":"Crit Rev Food Sci Nutr"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1038\/bjc.2011.47","volume":"104","author":"Damery S.","year":"2011","unstructured":"Damery S.; Gratus C.; Grieve R.; Warmington S.; Jones J.; Routledge P.; Greenfield S.; Dowswell G.; Sherriff J.; Wilson S.; The use of herbal medicines by people with cancer: a cross-sectional survey. Br J Cancer 2011,104(6),927-933","journal-title":"Br J Cancer"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1038\/s41598-018-25500-x","volume":"8","author":"Zhu H.","year":"2018","unstructured":"Zhu H.; Hao J.; Niu Y.; Liu D.; Chen D.; Wu X.; Molecular targets of Chinese herbs: a clinical study of metastatic colorectal cancer based on network pharmacology. Sci Rep 2018,8(1),7238","journal-title":"Sci Rep"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1002\/ptr.5213","volume":"28","author":"Alsanad S.M.","year":"2014","unstructured":"Alsanad S.M.; Williamson E.M.; Howard R.L.; Cancer patients at risk of herb\/food supplement-drug interactions: a systematic review. Phytother Res 2014,28(12),1749-1755","journal-title":"Phytother Res"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12906-016-1372-x","volume":"16","author":"Alsanad S.M.","year":"2016","unstructured":"Alsanad S.M.; Howard R.L.; Williamson E.M.; An assessment of the impact of herb-drug combinations used by cancer patients. BMC Complement Altern Med 2016,16(1),393","journal-title":"BMC Complement Altern Med"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1634\/theoncologist.11-7-742","volume":"11","author":"Meijerman I.","year":"2006","unstructured":"Meijerman I.; Beijnen J.H.; Schellens J.H.; Herb-drug interactions in oncology: focus on mechanisms of induction. Oncologist 2006,11(7),742-752","journal-title":"Oncologist"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1517\/17425255.2014.873786","volume":"10","author":"Haefeli W.E.","year":"2014","unstructured":"Haefeli W.E.; Carls A.; Drug interactions with phytotherapeutics in oncology. Expert Opin Drug Metab Toxicol 2014,10(3),359-377","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2174\/0929867325666180622141101","volume":"26","author":"Hahn R.Z.","year":"2019","unstructured":"Hahn R.Z.; Antunes M.V.; Verza S.G.; Perassolo M.S.; Suyenaga E.S.; Schwartsmann G.; Linden R.; Pharmacokinetic and pharmacogenetic markers of irinotecan toxicity. Curr Med Chem 2019,26(12),2085-2107","journal-title":"Curr Med Chem"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1007\/s40262-018-0644-7","volume":"57","author":"de Man F.M.","year":"2018","unstructured":"de Man F.M.; Goey A.K.L.; van Schaik R.H.N.; Mathijssen R.H.J.; Bins S.; Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics. Clin Pharmacokinet 2018,57(10),1229-1254","journal-title":"Clin Pharmacokinet"},{"key":"ref=137","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1124\/dmd.30.6.731","volume":"30","author":"Charasson V.","year":"2002","unstructured":"Charasson V.; Haaz M-C.; Robert J.; Determination of drug interactions occurring with the metabolic pathways of irinotecan. Drug Metab Dispos 2002,30(6),731-733","journal-title":"Drug Metab Dispos"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/dmd.115.066902","volume":"44","author":"Sprouse A.A.","year":"2016","unstructured":"Sprouse A.A.; van Breemen R.B.; Pharmacokinetic interactions between drugs and botanical dietary supplements. Drug Metab Dispos 2016,44(2),162-171","journal-title":"Drug Metab Dispos"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrclinonc.2009.146","volume":"6","author":"Emadi A.","year":"2009","unstructured":"Emadi A.; Jones R.J.; Brodsky R.A.; Cyclophosphamide and cancer: golden anniversary. Nat Rev Clin Oncol 2009,6(11),638-647","journal-title":"Nat Rev Clin Oncol"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/bjc.1985.10","volume":"51","author":"Gurtoo H.L.","year":"1985","unstructured":"Gurtoo H.L.; Bansal S.K.; Pavelic Z.; Struck R.F.; Effects of the induction of hepatic microsomal metabolism on the toxicity of cyclophosphamide. Br J Cancer 1985,51(1),67-75","journal-title":"Br J Cancer"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1097\/FPC.0b013e3282fc9766","volume":"18","author":"Ekhart C.","year":"2008","unstructured":"Ekhart C.; Doodeman V.D.; Rodenhuis S.; Smits P.H.M.; Beijnen J.H.; Huitema A.D.R.; Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008,18(6),515-523","journal-title":"Pharmacogenet Genomics"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.1365-2125.2008.03321.x","volume":"67","author":"Ekhart C.","year":"2009","unstructured":"Ekhart C.; Doodeman V.D.; Rodenhuis S.; Smits P.H.; Beijnen J.H.; Huitema A.D.; Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa. Br J Clin Pharmacol 2009,67(1),50-60","journal-title":"Br J Clin Pharmacol"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1124\/dmd.118.083766","volume":"47","author":"Ramirez D.A.","year":"2019","unstructured":"Ramirez D.A.; Collins K.P.; Aradi A.E.; Conger K.A.; Gustafson D.L.; Kinetics of cyclophosphamide metabolism in humans, dogs, cats, and mice and relationship to cytotoxic activity and pharmacokinetics. Drug Metab Dispos 2019,47(3),257-268","journal-title":"Drug Metab Dispos"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/tox.22215","volume":"32","author":"Man S.","year":"2017","unstructured":"Man S.; Qiu P.; Li J.; Zhang L.; Gao W.; Global metabolic profiling for the study of Rhizoma Paridis saponins-induced hepatotoxicity in rats. Environ Toxicol 2017,32(1),99-108","journal-title":"Environ Toxicol"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/03602532.2015.1124888","volume":"48","author":"Ma B.L.","year":"2016","unstructured":"Ma B.L.; Ma Y.M.; Pharmacokinetic herb-drug interactions with traditional Chinese medicine: progress, causes of conflicting results and suggestions for future research. Drug Metab Rev 2016,48(1),1-26","journal-title":"Drug Metab Rev"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jep.2019.01.040","volume":"235","author":"Xiao M.","year":"2019","unstructured":"Xiao M.; Qian C.; Luo X.; Yang M.; Zhang Y.; Wu C.; Mok C.; Lee P.; Zuo Z.; Impact of the Chinese herbal medicines on dual antiplatelet therapy with clopidogrel and aspirin: pharmacokinetics and pharmacodynamics outcomes and related mechanisms in rats. J Ethnopharmacol 2019,235,100-110","journal-title":"J Ethnopharmacol"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1111\/j.1742-7843.2009.00412.x","volume":"105","author":"Hellum B.H.","year":"2009","unstructured":"Hellum B.H.; Hu Z.; Nilsen O.G.; Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes. Basic Clin Pharmacol Toxicol 2009,105(1),58-63","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.cbi.2010.01.017","volume":"184","author":"Chien C.F.","year":"2010","unstructured":"Chien C.F.; Wu Y.T.; Lee W.C.; Lin L.C.; Tsai T.H.; Herb-drug interaction of Andrographis paniculata extract and andrographolide on the pharmacokinetics of theophylline in rats. Chem Biol Interact 2010,184(3),458-465","journal-title":"Chem Biol Interact"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3109\/03602532.2016.1151037","volume":"48","author":"Vanhove T.","year":"2016","unstructured":"Vanhove T.; Annaert P.; Kuypers D.R.; Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev 2016,48(1),88-112","journal-title":"Drug Metab Rev"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ejps.2019.04.026","volume":"134","author":"Qian C.Q.","year":"2019","unstructured":"Qian C.Q.; Zhao K.J.; Chen Y.; Liu L.; Liu X.D.; Simultaneously predict pharmacokinetic interaction of rifampicin with oral versus intravenous substrates of cytochrome P450 3A\/P glycoprotein to healthy human using a semi-physiologically based pharmacokinetic model involving both enzyme and transporter turnover. Eur J Pharm Sci 2019,134,194-204","journal-title":"Eur J Pharm Sci"},{"key":"ref=151","doi-asserted-by":"publisher","DOI":"10.1093\/ecam\/nep159","volume":"2011","author":"Kinoshita N.","year":"2011","unstructured":"Kinoshita N.; Yamaguchi Y.; Hou X.L.; Takahashi K.; Takahashi K.; Experimental adjustment on drug interactions through intestinal CYP3A activity in rat: impacts of kampo medicines repeat administered. Evid Based Complement Alternat Med 2011,2011","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1007\/s12272-011-1116-x","volume":"34","author":"Wang Y.","year":"2011","unstructured":"Wang Y.; Zou M.; Zhao N.; Ren J.; Zhou H.; Cheng G.; Effect of diallyl trisulfide on the pharmacokinetics of dipyridamole in rats. Arch Pharm Res 2011,34(11),1957-1964","journal-title":"Arch Pharm Res"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jep.2012.03.023","volume":"141","author":"Mekjaruskul C.","year":"2012","unstructured":"Mekjaruskul C.; Jay M.; Sripanidkulchai B.; Modulatory effects of Kaempferia parviflora extract on mouse hepatic cytochrome P450 enzymes. J Ethnopharmacol 2012,141(3),831-839","journal-title":"J Ethnopharmacol"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"667","DOI":"10.2174\/1389200211209050667","volume":"13","author":"Perera V.","year":"2012","unstructured":"Perera V.; Gross A.S.; McLachlan A.J.; Measurement of CYP1A2 activity: a focus on caffeine as a probe. Curr Drug Metab 2012,13(5),667-678","journal-title":"Curr Drug Metab"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.1124\/dmd.109.027433","volume":"37","author":"Lai L.","year":"2009","unstructured":"Lai L.; Hao H.; Wang Q.; Zheng C.; Zhou F.; Liu Y.; Wang Y.; Yu G.; Kang A.; Peng Y.; Wang G.; Chen X.; Effects of short-term and long-term pretreatment of Schisandra lignans on regulating hepatic and intestinal CYP3A in rats. Drug Metab Dispos 2009,37(12),2399-2407","journal-title":"Drug Metab Dispos"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.2174\/138920008786927802","volume":"9","author":"Fang H.","year":"2008","unstructured":"Fang H.; Wang K.; Zhang J.; Transcriptome and proteome analyses of drug interactions with natural products. Curr Drug Metab 2008,9(10),1038-1048","journal-title":"Curr Drug Metab"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.2174\/0929867323666160926150617","volume":"23","author":"Karahalil B.","year":"2016","unstructured":"Karahalil B.; Overview of systems biology and omics technologies. Curr Med Chem 2016,23(37),4221-4230","journal-title":"Curr Med Chem"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1039\/C8AN01574K","volume":"144","author":"Couvillion S.P.","year":"2019","unstructured":"Couvillion S.P.; Zhu Y.; Nagy G.; Adkins J.N.; Ansong C.; Renslow R.S.; Piehowski P.D.; Ibrahim Y.M.; Kelly R.T.; Metz T.O.; New mass spectrometry technologies contributing towards comprehensive and high throughput omics analyses of single cells. Analyst (Lond) 2019,144(3),794-807","journal-title":"Analyst (Lond)"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.jep.2019.01.030","volume":"234","author":"Guo M.Z.","year":"2019","unstructured":"Guo M.Z.; Wang T.Y.; Yang J.; Chang H.; Ji S.; Tang D.Q.; Interaction of clopidogrel and fufang danshen dripping pills assay in coronary heart disease based on non-target metabolomics. J Ethnopharmacol 2019,234,189-196","journal-title":"J Ethnopharmacol"}],"container-title":["Current Drug Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185076","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185076\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185076","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T09:59:19Z","timestamp":1696586359000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185076\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,30]]},"references-count":159,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12,30]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1389200221999200819144204","relation":{},"ISSN":["1389-2002"],"issn-type":[{"value":"1389-2002","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12,30]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-03-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-02","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-30","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}